Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer

Trial Profile

Cetuximab and Cisplatin with or without Paclitaxel in recurrent/metastatic head and neck cancer

Status: Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 08 Sep 2017

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Cetuximab (Primary) ; Cisplatin; Paclitaxel
  • Indications Head and neck cancer; Squamous cell cancer
  • Focus Biomarker; Pharmacogenomic; Therapeutic Use
  • Sponsors Merck Serono
  • Most Recent Events

    • 08 Sep 2017 Primary endpoint has been met. (Progression-free survival rate (Assessed at 6 and 12 months.)) as per results published in the Annals of Oncology
    • 08 Sep 2017 Results (data cut off: 30 Jun 2017) published in the Annals of Oncology
    • 08 Sep 2017 Status changed to active, no longer recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top